What the research found

The FDA has approved brepocitinib, an oral inhibitor targeting two immune signalling pathways (TYK2 and JAK1), for adults with dermatomyositis who have already tried at least one other treatment. This is the first oral therapy approved for any idiopathic inflammatory myopathy.

The approval rested on the VALOR trial, which enrolled 241 adults—most of whom were already taking glucocorticoids and had failed prior therapies. Brepocitinib improved muscle strength and function compared to placebo, with about 1 in 4 people achieving a major response and 1 in 4 achieving moderate improvement. Notably, it also reduced the characteristic skin symptoms and itching that often accompany the condition, with patients reporting meaningful improvements in quality of life.

The drug did increase serious infection risk roughly 1 in 11 treated patients. While it allowed some reduction in glucocorticoid doses over the study year, the steroid-sparing effect was modest. The trial did not detect signals for blood clots, heart attacks, or cancer, though the study was not designed to pick up rare safety events.

Why it matters for you

If you have dermatomyositis and track inflammatory markers or autoimmune activity, brepocitinib represents a new option—particularly relevant if you've had inadequate responses to conventional immunosuppressants. The fact that it improved both muscle function and skin symptoms suggests it addresses the underlying inflammation rather than masking symptoms alone. Users monitoring CK, muscle strength assessments, or skin involvement as biomarkers may see measurable improvements.

The infection risk is the practical trade-off. MyKine users who optimise immune function through sleep, training, and supplement stacks should understand that JAK inhibition will work against these efforts in specific ways: expect slightly higher infection frequency and need to monitor for signs of opportunistic pathogens. This is different from TNF inhibitors, where aggressive steroid reduction sometimes offsets the immunosuppressive hit.

The modest steroid-sparing effect is also worth noting. If you're currently on high glucocorticoid doses hoping to taper with a new DMARD, this drug alone may not get you there—you may need additional therapies or longer timescales. Anyone considering brepocitinib should discuss the full JAK-class safety profile (cardiovascular and malignancy warnings) with their clinician, as these remain theoretical concerns that haven't yet been ruled out in this patient group.

Caveats

  • Trial duration was roughly one year; longer-term safety and efficacy unknown
  • Study was not powered to detect rare safety signals (blood clots, malignancy), so these cannot be ruled out
  • Modest steroid-sparing effect may reflect trial design (low starting doses, fixed tapering) rather than the drug's true potential
  • No head-to-head comparisons with other immunosuppressants in dermatomyositis
  • Serious infection risk is real and will apply to individual users; observational data to refine this estimate are still emerging